These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19373667)

  • 21. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 22. Productivity counts--but the definition is key.
    Mervis J
    Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
    [No Abstract]   [Full Text] [Related]  

  • 23. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 24. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2015; (992):1-210, back cover. PubMed ID: 26118121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 26. An uncertain future for cardiovascular drug development?
    Garber AM
    N Engl J Med; 2009 Mar; 360(12):1169-71. PubMed ID: 19297568
    [No Abstract]   [Full Text] [Related]  

  • 27. The case for standardizing the appearance of bioequivalent medications.
    Engelberg AB
    J Manag Care Pharm; 2011 May; 17(4):321-3. PubMed ID: 21534643
    [No Abstract]   [Full Text] [Related]  

  • 28. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):701. PubMed ID: 24073621
    [No Abstract]   [Full Text] [Related]  

  • 29. Basic requirements for investigational new drug and new drug application approval for an antioxidant compound in cardiovascular disease.
    Witztum JL
    Am J Cardiol; 1998 Apr; 81(8A):50F-51F. PubMed ID: 9604908
    [No Abstract]   [Full Text] [Related]  

  • 30. Manufacturing of biopharmaceuticals and implications for biosimilars.
    Wurm FM
    Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
    [No Abstract]   [Full Text] [Related]  

  • 31. 'Time to stop bleating' about medicines.
    Vet Rec; 1995 Oct; 137(17):414-5. PubMed ID: 8560697
    [No Abstract]   [Full Text] [Related]  

  • 32. What's in a drug name?
    Wick JY
    J Am Pharm Assoc (2003); 2004; 44(1):12-4. PubMed ID: 14965147
    [No Abstract]   [Full Text] [Related]  

  • 33. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 34. Copycats gear up to dog biotech brands.
    Wadman M
    Nature; 2006 Oct; 443(7111):496-7. PubMed ID: 17024060
    [No Abstract]   [Full Text] [Related]  

  • 35. WHO tries to tackle problem of counterfeit medicines in Asia.
    Pincock S
    BMJ; 2003 Nov; 327(7424):1126. PubMed ID: 14615319
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 37. An audience with... Thomas Lönngren.
    Lönngren T
    Nat Rev Drug Discov; 2006 Mar; 5(3):182. PubMed ID: 16557656
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents.
    Skovronsky D
    J Nucl Med; 2008 Jun; 49(6):47N-48N. PubMed ID: 18511825
    [No Abstract]   [Full Text] [Related]  

  • 39. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature.
    Walsh G
    Eur J Pharm Sci; 2002 Mar; 15(2):135-8. PubMed ID: 11849909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.